Search
Search Results
##search.searchResults.foundPlural##
-
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2820PDF: 831HTML: 2334 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2416PDF: 1127HTML: 2033Characteristic of study group: 246 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
2064PDF: 877HTML: 258 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2423PDF: 2157HTML: 239 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2613PDF: 861HTML: 1756 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3446PDF: 1012HTML: 4237 -
TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
3540PDF: 1335HTML: 8404 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
2423PDF: 641HTML: 380 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2427PDF: 1897HTML: 1012 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
2452PDF: 798HTML: 2155Untitled: 276Untitled: 199Untitled: 231Untitled: 212Untitled: 221Untitled: 245Untitled: 234 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2656PDF: 1797HTML: 708 -
Magnusiomyces capitatus Breakthrough Infection in Allogeneic Hematopoietic Cell Transplant Recipients Receiving Echinocandin Prophylaxis: Clinical Features, Management, and Review of the Literature
105PDF: 169Suppl. Files: 22Html: 107Html Suppl. Files: 81 -
NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014
2274PDF: 1080HTML: 4109Cover Letter: 270Figure 1: 280Figure 2: 272Table 1: 257 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1798PDF: 2034Suppl. Files: 280HTML: 116 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7950PDF: 2522HTML: 2155Table 1.: 275Table 2.: 288Table 3.: 267Table 4.: 263 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1203PDF: 1239Suppl. Files: 604HTML: 106 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3971PDF: 1766HTML: 11938Figures Haase: 279 -
EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA
2359PDF: 1067HTML: 4991 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3855PDF: 973HTML: 6888 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4621Suppl. Files: 1257PDF: 1161Html: 313 -
Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients
1060PDF: 607HTML: 2231Cover Letter: 237 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4460PDF: 1459HTML: 2206 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
5926PDF: 1608HTML: 1677Untitled: 283 -
UPDATE ON THE LABORATORY DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS
2563PDF: 1520HTML: 2031 -
NF- ?B Essential Modulator Deficiency Leading to Disseminated Cutaneous Atypical Mycobacteria
2229PDF: 1181HTML: 10765Untitled: 243







